Jakrif-10 Tablet

About Jakrif-10 Tablet

Jakrif-10 is a tablet medicine whose generic name is tofacitinib. It belongs to a group of medicines called immunosuppressants and is prescribed for adults with certain long-term joint conditions.

There are 13 brands of Tofacitinib listed in Bangladesh. The lowest listed price is Tofacit 5 mg Tablet at ৳ 30.00 per unit.

What is Jakrif-10 Tablet?

Jakrif-10 is a 10 mg tablet containing tofacitinib, made by Renata PLC. It is classed as an immunosuppressant. In the body it works by blocking janus kinase enzymes, which are part of a signalling pathway that drives inflammation. This medicine is used in adults with moderately to severely active rheumatoid arthritis who have not responded well to, or could not tolerate, methotrexate. It may be prescribed alone or together with methotrexate or other nonbiologic disease-modifying antirheumatic drugs. Only a registered doctor can decide whether it suits a particular patient.

Uses of Jakrif-10

Jakrif-10 is used for adults with moderately to severely active rheumatoid arthritis whose earlier treatment with methotrexate did not work well enough or was not tolerated. It can be given on its own or alongside methotrexate or other nonbiologic disease-modifying antirheumatic drugs. It is not a painkiller for everyday aches, and it should not be started without a doctor's assessment.

How to use Jakrif-10

Jakrif-10 is a tablet that is swallowed. The doctor decides the dose, how often it is taken and how long the course lasts, and may adjust these depending on the patient's condition, kidney or liver function and other medicines being taken. Do not change the schedule on your own. Ask the doctor or pharmacist if a dose is missed or if you are unsure how to take it.

Side effects of Jakrif-10

In clinical trials, the most commonly reported side effects during the first three months were upper respiratory tract infections, headache, diarrhoea and nasopharyngitis. Because this medicine affects the immune system, serious infections can occur. Tell your doctor promptly about fever, persistent cough, or any sign of infection. Laboratory monitoring may be advised because the medicine can affect blood counts, liver enzymes and lipids.

Safety and precautions

Do not take Jakrif-10 during an active serious infection, including a localised one. It should be used with caution in people who may be at higher risk of gastrointestinal perforation. Live vaccines should be avoided while taking it. Blood monitoring may be needed. The doctor decides whether it is suitable in pregnancy or breastfeeding; both need to be discussed first. People with kidney or liver problems, or who take other medicines, should tell the doctor before starting.

Frequently asked questions

How should Jakrif-10 be taken?

It is a tablet that is swallowed. The doctor decides the dose, how often it is taken and how long it should be continued, and may adjust these based on the patient's health and other medicines. Follow the doctor's instructions and ask the pharmacist if anything is unclear.

What is Jakrif-10 used for and what kind of medicine is it?

Jakrif-10 contains tofacitinib and is an immunosuppressant. It is used in adults with moderately to severely active rheumatoid arthritis who have not responded well to, or could not tolerate, methotrexate. It may be used alone or with methotrexate or other nonbiologic DMARDs.

Is Jakrif-10 safe in pregnancy or breastfeeding?

Pregnancy and breastfeeding should be discussed with the doctor before taking this medicine. The doctor will weigh the possible benefits against the possible risks to the baby, and will advise whether breastfeeding should be stopped. Do not decide on your own.

What should I tell my doctor before starting Jakrif-10?

Tell the doctor about any current or recent infection, kidney or liver problems, and all other medicines you take, including over-the-counter products. Also mention if you are pregnant, planning pregnancy or breastfeeding, and ask about vaccines, since live vaccines should be avoided with this medicine.

Indications

Rheumatoid Arthritis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic ... Read moreRheumatoid Arthritis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).

Psoriatic Arthritis: Tofacitinib is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).

Ulcerative Colitis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).

Pharmacology

Rheumatoid arthritis is an autoimmune disease characterized by a dysregulation of pro-inflammatory cytokines including IL7, IL15, IL21, IL6, IFN-alpha, and IFN-beta. (3) Cytokines signalling results in tissue inflammation and joint damage by stimulating the recruitment and activation of immune cells via the janus kinase signalling pathway.

Tofacitinib is a partial and reversible janus kinase (JAK) inihibitor that will prevent the body from responding to cytokine signals. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs. The JAK-STAT signalling pathway is involved in the transcription of cells involved in hematopoiesis, and immune cell function. Tofacitinib works therapeutically by inhibiting the JAK-STAT pathway to decrease the inflammatory response. However, there is evidence to suggest that it may also achieve efficacy via other pathways as well.

Dosage & Administration

Rheumatoid Arthritis: Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily. Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib 5 mg once daily.

Psoriatic Arthritis (in combination with nonbiologic DMARDs): Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily.  Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib 5 mg once daily.

Ulcerative Colitis: Tofacitinib 10 mg twice daily for at least 8 weeks; then 5 or 10 mg twice daily. Discontinue after 16 weeks of 10 mg twice daily, if adequate therapeutic benefit is not achieved. Use the lowest effective dose to maintain response.

Interaction

  • Potent inhibitors of Cytochrome P450 3A4 (CYP3A4) (e.g., Ketoconazole)
  • Recommended dose is Tofacitinib 5 mg once daily: One or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole)
  • Recommended dose is Tofacitinib 5 mg once daily Potent CYP inducers (e.g.Rifampin): May result in loss of or reduced clinical response.

Side Effects

The most commonly reported adverse reactions during the first 3 months in controlled clinical trials (occurring in greater than or equal to 2% of patients treated with Tofacitinib monotherapy or in combination with DMARDs) were upper respiratory tract infections, headache, diarrhea and nasopharyngitis.

Pregnancy & Lactation

Pregnancy Category C. There are no adequate and well controlled studies in pregnant women. Tofacitinib should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

It is not known whether Tofacitinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Tofacitinib, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug for the mother

Precautions & Warnings

  • Serious Infections: Avoid use of Tofacitinib during an active serious infection, including localized infections. 
  • Gastrointestinal Perforations: Use with caution in patients that may be at increased risk.
  • Laboratory Monitoring: Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids.
  • Immunizations: Live vaccines: Avoid use with Tofacitinib.
  • Do not initiate Tofacitinib if absolute lymphocyte count <500 cells/mm3, an absolute neutrophil count (ANC) <1000 cells/mm3 or hemoglobin <9 gm/dL.

Storage Conditions

Store below 30°C. Protect from light & moisture. Keep all medicines out of the reach of children.

Alternative brands of Tofacitinib

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.